FDA Cancer Trial Guidelines: Prioritizing Overa...

By João L. Carapinha

October 23, 2025

The FDA cancer trial guidelines from August 2025 emphasize overall survival (OS) as the key endpoint for oncology drug approvals. If you're wondering how these FDA cancer trial guidelines impact patient outcomes in treatment trials, they shift foc...
C. auris Outbreak in Europe: Alarming Spread and Rising Resistance
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in C...
AMALFI Trial: How Patch-Based ECG Monitoring Could Transform Remote Atrial Fi...
FDA Guidance on Overall Survival Assessment in Oncology Trials
Guiding the Future of Digital Cardiac Rehabilitation: NICE’s Conditiona...
Unlocking Self-Care South Africa: Strategies and Challenges in Healthcare Reform
Urgent Care Effectiveness: Exploring Canadian Centre Models and Health System...
France’s HAS Denies Ribociclib Breast Cancer Therapy for Early HR+/HER2...
AI in Real-World Evidence: Insights from Mitch Higashi
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants
ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in L...